Table 1

Characteristics of randomised controlled trials included

First authorYearDiseaseTiming of assessmentComparisonEA
Kim162007RAWeek 24PBO vs ADANo
Rutgeerts172005UCWeek 54PBO vs IFXYes
Baranauskaite182012PsAWeek 16MTX vs IFX+MTXYes
Barker192011PsWeek 24MTX vs IFX
Braun202002ASWeek 12PBO vs IFXNo
Breedveld212006RAYear 2MTX vs ADA/ADA+MTX
Chen222009RAWeek 12MTX vs ADA+MTXNo
Colombel232010CDWeek 20AZA vs IFX/IFX+AZA
Couriel242009GvHMonth 6MP vs IFX+MPNo
Judson252014SarcoidosisWeek 44PBO vs GOL
Kavanaugh262013RAWeek 26PBO+MTX vs ADA+MTXYes
Kennedy272014RAWeek 12PBO vs ADANo
Keystone282004RAWeek 52PBO+MTX vs ADA+MTXNo
Keystone292008RAWeek 52PBO+MTX vs CZP+MTXYes
Maini301999RAWeek 102DMARDs vs IFX+DMARDsNo
Nam312014RAWeek 78PBO+MTX vs IFX+MTXNo
Reich322012PsWeek 12PBO vs CZPNo
Schiff332014RAYear 2ABA+MTX vs ADA+MTXNo
Schiff342008RAYear 1PBO+MTX vs IFX+MTXYes
Sieper352014ASWeek 28PBO+NPX vs IFX+NPXYes
Smolen362009RAWeek 24PBO+MTX vs CZP+MTXYes
St Clair372004RAWeek 54PBO+MTX vs IFX+MTXNo
Suzuki382014UCWeek 8PBO vs ADANo
Tam392012RAMonth 6MTX vs IFX+MTXYes
Van Den Bosch402002ASWeek 12PBO vs IFX-
van der Heijde412007RAYear 3MTX vs ETN/ETN+MTXYes
van Vollenhoven422011RAWeek 24PBO+MTX vs ADA+MTXYes
Wenzel432009AsthmaWeek 76PBO vs GOLNo
Westhovens442006RAWeek 22PBO+MTX vs IFX+MTXYes
  • ABA, abatacept; ADA, adalimumab; AS, ankylosing spondylitis; AZA, azathioprine; CD, Crohn's disease; CZP, certolizumab pegol; DMARDs, disease-modifying anti-rheumatic drugs; EA, endemic area of TB; ETN, etanercept; GOL, golimumab; GvH, graft-versus-host disease; IFX, infliximab; MP, methylprednisolone; MTX, methotrexate; NPX, naproxen; PBO, placebo; Ps, plaque psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; UC, ulcerative colitis.